ArticleFrontiers in pharmacology2026
Biomimetic dexamethasone-loaded nanoparticles attenuate sepsis-induced acute lung injury.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-induced acute lung injury (ALI) is a severe complication characterized by uncontrolled inflammation and high mortality, yet effective targeted therapies remain limited. Notably, acute myocardial infarction (MI) frequently coexists with or exacerbates ALI through shared inflammatory pathways. Dexamethasone (Dex) exerts potent anti-inflammatory effects but its clinical application is limited by non-specific biodistribution and dose-dependent off-target toxicities. Methods: We developed a biomimetic nanoplatform Dex@mPLGA by coating dexamethasone-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles with RAW264.7 macrophage membranes. The physicochemical properties of Dex@mPLGA were systematically characterized. Cellular uptake, cytotoxicity, anti-inflammatory, antioxidant, anti-apoptotic, and immunomodulatory effects were evaluated in LPS-stimulated RAW264.7 cells. Results: Dex@mPLGA exhibited a core-shell structure with an average particle size of 147.3 nm, negative surface charge, 3.2% drug loading, 74.6% encapsulation efficiency, good colloidal stability, and sustained Dex release. SDS-PAGE analysis supported the retention of macrophage membrane protein components in the final formulation. Dex@mPLGA was internalized by RAW264.7 macrophages in a time-dependent manner and showed minimal cytotoxicity at the tested concentrations. In LPS-stimulated macrophages, Dex@mPLGA alleviated inflammatory and oxidative stress-related responses relative to the LPS model, including improved cell viability, reduced ROS and MDA levels, decreased pro-inflammatory cytokine and NO production, increased IL-10 secretion, reduced apoptosis, restored proliferative activity, and modulation of macrophage polarization. Direct comparison with uncoated Dex@PLGA showed that the additional Conclusion: Dex@mPLGA represents an innovative biomimetic Dex delivery platform with therapeutic potential for sepsis-induced ALI. Its efficacy is likely associated with PLGA-mediated sustained Dex delivery, macrophage-associated uptake, selected membrane-related immunoregulatory benefits, and improved pulmonary accumulation
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.